LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$0.99
-0.04 (-3.45%)
Financial Highlights (FY 2026)
Revenue
13.17M
Net Income
-70,176,889
Gross Margin
92.5%
Profit Margin
-240.2%
Rev Growth
+61.1%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 92.5% | 92.5% | 47.8% | 47.8% |
| Operating Margin | -276.5% | -248.9% | -28.4% | -27.0% |
| Profit Margin | -240.2% | -228.2% | -28.2% | -24.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.17M | 8.17M | 231.61M | 228.84M |
| Gross Profit | 12.18M | 7.56M | 110.75M | 109.43M |
| Operating Income | -36,404,291 | -20,335,068 | -65,786,728 | -61,682,578 |
| Net Income | -70,176,889 | -39,200,099 | -65,233,876 | -55,561,821 |
| Gross Margin | 92.5% | 92.5% | 47.8% | 47.8% |
| Operating Margin | -276.5% | -248.9% | -28.4% | -27.0% |
| Profit Margin | -240.2% | -228.2% | -28.2% | -24.3% |
| Rev Growth | +61.1% | +61.1% | -6.2% | +9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 190.3K | 190.3K | 89.39M | 91.16M |
| Total Equity | 126.90M | 126.90M | 127.69M | 122.13M |
| D/E Ratio | 0.00 | 0.00 | 0.70 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -39,676,249 | -23,394,014 | -95,106,936 | -92,494,345 |
| Free Cash Flow | — | — | -33,113,271 | -35,128,048 |